Regulation of 11ß-hydroxysteroid dehydrogenase type 2 by MicroRNA

Hypertension

Volumn 64, Issue 4, 2014, Pages 860-866

  Rezaei, Mina ^a   Andrieu, Thomas ^a   Neuenschwander, Samuel ^a,b   Bruggmann, Rémy ^a   Mordasini, David ^a   Frey, Felix J ^a   Vogt, Bruno ^a   Frey, Brigitte M ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Hypertension; Kidney; MicroRNAs; Mineralocorticoids

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; 3' UNTRANSLATED REGION; MICRORNA; SALT INTAKE;

3' UNTRANSLATED REGION; ANIMAL; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HT 29 CELL LINE; HUMAN; HYPERTENSION; KIDNEY COLLECTING TUBULE; KIDNEY CORTEX; MALE; METABOLISM; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALT INTAKE; SPECIES DIFFERENCE; SPRAGUE DAWLEY RAT; TUMOR CELL LINE; WISTAR RAT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; 3' UNTRANSLATED REGIONS; ANIMALS; CELL LINE, TUMOR; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HT29 CELLS; HUMANS; HYPERTENSION; KIDNEY CORTEX; KIDNEY TUBULES, COLLECTING; MALE; MICRORNAS; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SODIUM CHLORIDE, DIETARY; SPECIES SPECIFICITY;

EID: 84914695392     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.00002     Document Type: Article

References (40)

1. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol. 1994;105: R11-R17.
2. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: Target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242: 583-585.
3. White PC, Mune T, Agarwal AK. 11 beta-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev. 1997;18: 135-156.
4. Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR, Mullins JJ. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J Clin Invest. 1999;103: 683-689.
5. Lovati E, Ferrari P, Dick B, Jostarndt K, Frey BM, Frey FJ, Schorr U, Sharma AM. Molecular basis of human salt sensitivity: The role of the 11beta-hydroxysteroid dehydrogenase type 2. J Clin Endocrinol Metab. 1999;84: 3745-3749.
6. Ferrari P, Sansonnens A, Dick B, Frey FJ. In vivo 11beta-HSD-2 activity: Variability, salt-sensitivity, and effect of licorice. Hypertension. 2001;38: 1330-1336.
7. Atanasov AG, Ignatova ID, Nashev LG, Dick B, Ferrari P, Frey FJ, Odermatt A. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: A novel mechanism of apparent mineralocorticoid excess. J Am Soc Nephrol. 2007;18: 1262-1270.
8. Stauffer AT, Rochat MK, Dick B, Frey FJ, Odermatt A. Chenodeoxycholic acid and deoxycholic acid inhibit 11 beta-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J Biol Chem. 2002;277: 26286-26292.
9. Quattropani C, Vogt B, Odermatt A, Dick B, Frey BM, Frey FJ. Reduced activity of 11 beta-hydroxysteroid dehydrogenase in patients with cholestasis. J Clin Invest. 2001;108: 1299-1305.
10. Heiniger CD, Kostadinova RM, Rochat MK, Serra A, Ferrari P, Dick B, Frey BM, Frey FJ. Hypoxia causes down-regulation of 11 betahydroxysteroid dehydrogenase type 2 by induction of Egr-1. FASEB J. 2003;17: 917-919.
11. Lanz CB, Causevic M, Heiniger C, Frey FJ, Frey BM, Mohaupt MG. Fluid shear stress reduces 11ss-hydroxysteroid dehydrogenase type 2. Hypertension. 2001;37: 160-169.
12. N'Gankam V, Uehlinger D, Dick B, Frey BM, Frey FJ. Increased cortisol metabolites and reduced activity of 11beta-hydroxysteroid dehydrogenase in patients on hemodialysis. Kidney Int. 2002;61: 1859-1866.
13. Lauterburg M, Escher G, Dick B, Ackermann D, Frey FJ. Uninephrectomy reduces 11ß-hydroxysteroid dehydrogenase type 1 and type 2 concomitantly with an increase in blood pressure in rats. J Endocrinol. 2012;214: 373-380.
14. Alikhani-Koupaei R, Fouladkou F, Fustier P, Cenni B, Sharma AM, Deter HC, Frey BM, Frey FJ. Identification of polymorphisms in the human 11beta-hydroxysteroid dehydrogenase type 2 gene promoter: Functional characterization and relevance for salt sensitivity. FASEB J. 2007;21: 3618-3628.
15. Zaehner T, Plueshke V, Frey BM, Frey FJ, Ferrari P. Structural analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene in end-stage renal disease. Kidney Int. 2000;58: 1413-1419.
16. Nawrocki AR, Goldring CE, Kostadinova RM, Frey FJ, Frey BM. In vivo footprinting of the human 11beta-hydroxysteroid dehydrogenase type 2 promoter: Evidence for cell-specific regulation by Sp1 and Sp3. J Biol Chem. 2002;277: 14647-14656.
17. Alikhani-Koopaei R, Fouladkou F, Frey FJ, Frey BM. Epigenetic regulation of 11 beta-hydroxysteroid dehydrogenase type 2 expression. J Clin Invest. 2004;114: 1146-1157.
18. Kostadinova RM, Nawrocki AR, Frey FJ, Frey BM. Tumor necrosis factor alpha and phorbol 12-myristate-13-acetate down-regulate human 11betahydroxysteroid dehydrogenase type 2 through p50/p50 NF-kappaB homodimers and Egr-1. FASEB J. 2005;19: 650-652.
19. Li JN, Ge YC, Yang Z, Guo CM, Duan T, Myatt L, Guan H, Yang K, Sun K. The Sp1 transcription factor is crucial for the expression of 11betahydroxysteroid dehydrogenase type 2 in human placental trophoblasts. J Clin Endocrinol Metab. 2011;96: E899-E907.
20. Escher G, Vogt B, Beck T, Guntern D, Frey BM, Frey FJ. Reduced 11betahydroxysteroid dehydrogenase activity in the remaining kidney following nephrectomy. Endocrinology. 1998;139: 1533-1539.
21. Shackleton CH. Mass spectrometry in the diagnosis of steroid-related disorders and in hypertension research. J Steroid Biochem Mol Biol. 1993;45: 127-140.
22. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, Ferbeyre G, Chartrand P. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2007;282: 2135-2143.
23. Dickinson BA, Semus HM, Montgomery RL, Stack C, Latimer PA, Lewton SM, Lynch JM, Hullinger TG, Seto AG, van Rooij E. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail. 2013;15: 650-659.
24. Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006;38: 1060-1065.
25. Luo Y, Wang C, Chen X, Zhong T, Cai X, Chen S, Shi Y, Hu J, Guan X, Xia Z, Wang J, Zen K, Zhang CY, Zhang C. Increased serum and urinary microRNAs in children with idiopathic nephrotic syndrome. Clin Chem. 2013;59: 658-666.
26. Vogt B, Dick B, N'Gankam V, Frey FJ, Frey BM. Reduced 11betahydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome. J Clin Endocrinol Metab. 1999;84: 811-814.
27. Liu Y, Taylor NE, Lu L, Usa K, Cowley AW, Jr, Ferreri NR, Yeo NC, Liang M. Renal medullary microRNAs in Dahl salt-sensitive rats: MiR-29b regulates several collagens and related genes. Hypertension. 2010;55: 974-982.
28. Li D, Lu Z, Jia J, Zheng Z, Lin S. Changes in microRNAs associated with podocytic adhesion damage under mechanical stress. J Renin Angiotensin Aldosterone Syst. 2013;14: 97-102.
29. Belaguli NS, Sepulveda JL, Nigam V, Charron F, Nemer M, Schwartz RJ. Cardiac tissue enriched factors serum response factor and GATA-4 are mutual coregulators. Mol Cell Biol. 2000;20: 7550-7558.
30. Han M, Yang Z, Sayed D, He M, Gao S, Lin L, Yoon S, Abdellatif M. GATA4 expression is primarily regulated via a miR-26b-dependent posttranscriptional mechanism during cardiac hypertrophy. Cardiovasc Res. 2012;93: 645-654.
31. Gennarino VA, D'Angelo G, Dharmalingam G, Fernandez S, Russolillo G, Sanges R, Mutarelli M, Belcastro V, Ballabio A, Verde P, Sardiello M, Banfi S. Identification of microRNA-regulated gene networks by expression analysis of target genes. Genome Res. 2012;22: 1163-1172.
32. Lin DH, Yue P, Pan C, Sun P, Wang WH. MicroRNA 802 stimulates ROMK channels by suppressing caveolin-1. J Am Soc Nephrol. 2011;22: 1087-1098.
33. Chau BN, Xin C, Hartner J, et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci Transl Med. 2012;4: 121ra18.
34. Shang Y, Yang X, Zhang R, Zou H, Zhao R. Low amino acids affect expression of 11ß-HSD2 in BeWo cells through leptin-activated JAKSTAT and MAPK pathways. Amino Acids. 2012;42: 1879-1887.
35. Witkos TM, Koscianska E, Krzyzosiak WJ. Practical Aspects of microRNA Target Prediction. Curr Mol Med. 2011;11: 93-109.
36. Vinson C, Chatterjee R. CG methylation. Epigenomics. 2012;4: 655-663.
37. Bátkai S, Thum T. MicroRNAs in hypertension: Mechanisms and therapeutic targets. Curr Hypertens Rep. 2012;14: 79-87.
38. Guo L, Qiu Z, Wei L, Yu X, Gao X, Jiang S, Tian H, Jiang C, Zhu D. The microRNA-328 regulates hypoxic pulmonary hypertension by targeting at insulin growth factor 1 receptor and L-type calcium channel-a1C. Hypertension. 2012;59: 1006-1013.
39. Godwin JG, Ge X, Stephan K, Jurisch A, Tullius SG, Iacomini J. Identification of a microRNA signature of renal ischemia reperfusion injury. Proc Natl Acad Sci U S A. 2010;107: 14339-14344.
40. Kotlo KU, Hesabi B, Danziger RS. Implication of microRNAs in atrial natriuretic peptide and nitric oxide signaling in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2011;301: C929-C937.